In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.
about
Critical evaluation of ceftolozane-tazobactam for complicated urinary tract and intra-abdominal infectionsCeftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infectionsImpact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target.In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.An optimized mouse thigh infection model for enterococci and its impact on antimicrobial pharmacodynamics.Plasma and epithelial lining fluid pharmacokinetics of ceftolozane and tazobactam alone and in combination in mice.Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of InfectionCombinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations.Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model.Pharmacodynamics of Ceftolozane Combined with Tazobactam against Enterobacteriaceae in a Neutropenic Mouse Thigh Model.In Vitro-In Vivo Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Escherichia coliNew β-lactam-β-lactamase inhibitor combinations in clinical development.Current research in empirical therapy for febrile neutropenia in cancer patients: what should be necessary and what is going on.β-Lactamase inhibitors: a review of the patent literature (2010 - 2013).Combating multidrug-resistant Gram-negative bacterial infections.Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections.Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination.Multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin-resistant enterococci: Three major threats to hematopoietic stem cell transplant recipients.Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance.Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections.Updates in the Management of Cephalosporin-Resistant Gram-Negative Bacteria.Ceftolozane/tazobactam for the treatment of complicated urinary tract and intra-abdominal infections.Pharmacokinetics and Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients with Lower Limb Infections and Healthy Adult Volunteers.In Vitro-In Vivo Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Klebsiella pneumoniae Strains.Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.Considerations About Antimicrobial Stewardship in Settings with Epidemic Extended-Spectrum β-Lactamase-Producing or Carbapenem-Resistant Enterobacteriaceae.Efficacy of ceftolozane in a murine model of Pseudomonas aeruginosa acute pneumonia: in vivo antimicrobial activity and impact on host inflammatory response.
P2860
Q26747429-2617C7DA-6E34-4627-AC71-9D2D495779EEQ28069563-6C53E827-5C58-43CC-95B4-762D657E9BE5Q34299064-4E9A5294-4D20-4810-9D57-FF331B3B4BA9Q34320027-A36847B5-560A-499F-BD2A-C497A365F19AQ34393008-B3524BD3-ABDE-4EC8-AFF8-08F22C0A451BQ34922257-3C2CE5E9-53AD-4674-8D0C-2041B1E20118Q35607735-4F13931A-716C-4CE4-9639-E199DDD4788DQ36438924-EF086F44-6AAE-4320-B542-F6D2529B59AAQ36730017-CD6BB0B8-51E8-40CE-81C8-CD7ADE0E8115Q36785886-37FA3610-2016-42D9-B53B-B192464ACBF8Q37428654-8A578884-6035-4A9A-A02F-6C913A2D0092Q37428761-B8FD21FF-A794-4B29-9CC9-500AD27FBE79Q38076455-26890E26-4E81-41E0-BCF7-63ED5E8DF344Q38115356-7F2E0D40-8CF4-40F2-BEB6-9164E430A48CQ38130715-D827FCB0-C7BE-4085-8F83-EE046D20153FQ38161570-34F522BB-A365-437E-BC62-236354868B34Q38241417-09AC337D-1B82-465C-888B-AF501C3ABB9FQ38541624-F2174640-0F85-4089-9A51-7842C4E0665FQ38544744-D3CD90EF-AB93-4860-BB0A-04E67259F39CQ38620812-BA0F3757-1A16-49C0-9DD9-658B61CCDAC4Q38672016-E425B0B9-1CFE-4FDE-AB67-03E5F6863C49Q38690748-759AC866-4D32-41A1-8C56-D9A08CDECC6EQ38981397-A8BD6327-57E5-43AD-B88B-0289F15C1F1DQ39037981-BD5E5785-83EE-4DED-9A44-4F2247F09F76Q40052714-E968FE50-B378-4FAE-AFD2-A8074D263561Q40175217-A2D93C10-59C8-4E88-A3A2-334BEEC91E43Q40755542-F0BE0280-A34C-4857-AF7A-D768FE587C02Q41004466-F9D3CAF2-6363-453F-B736-FD8C68945FE7Q44053339-475FC95F-253D-486E-9D81-1125B220207E
P2860
In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
In vivo comparison of CXA-101 ...... verse gram-negative organisms.
@ast
In vivo comparison of CXA-101 ...... verse gram-negative organisms.
@en
type
label
In vivo comparison of CXA-101 ...... verse gram-negative organisms.
@ast
In vivo comparison of CXA-101 ...... verse gram-negative organisms.
@en
prefLabel
In vivo comparison of CXA-101 ...... verse gram-negative organisms.
@ast
In vivo comparison of CXA-101 ...... verse gram-negative organisms.
@en
P2093
P2860
P356
P1476
In vivo comparison of CXA-101 ...... verse gram-negative organisms.
@en
P2093
Catharine C Bulik
Christina A Sutherland
David P Nicolau
Pamela R Tessier
Rebecca A Keel
P2860
P304
P356
10.1128/AAC.01752-10
P407
P577
2011-11-07T00:00:00Z